CLOs on the Move


 
Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.pepgen.com
  • 245 Main Street 2nd Floor
    Cambridge, MA USA 02142
  • Phone: 781.797.0979

Executives

Name Title Contact Details
Mary Beth Delena
General Counsel and Secretary Profile

Similar Companies

CoMentis

CoMentis is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hepion Pharmaceuticals

Hepion Pharmaceuticals is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. T

Biocompare

Biocompare is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Promega Corporation

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's 1,450 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis,

Mammoth Biosciences

Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasΦ, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.